Childhood obesity has reached unprecedented levels, and evidence now points to adipose tissue health—rather than body size alone—as a core determinant of metabolic risk in children. Recent research underscores marked heterogeneity in obesity phenotypes and treatment outcomes, highlighting the need for precision medicine approaches. Adipose tissue dysfunction , not just excess, predicts the onset of metabolic syndrome, type 2 diabetes, and related complications. The development of individualized risk stratification tools , grounded in measures of adipose tissue biology and novel biomarkers, is critical to optimally target intensive lifestyle, pharmacologic, or surgical interventions.
Expanding multi-omics and developmental studies could enable more personalized, effective, and equitable care for pediatric obesity and its long-term sequelae. To read more Click here . ##Reference##…
